Skip to main content
. 2022 Mar 22;12:61–73. doi: 10.2147/DNND.S313825

Table 3.

Main Findings of the Oral Ponesimod versus Teriflunomide in Relapsing Multiple Sclerosis (OPTIMUM)

Relative Risk*
Ponesimod versus Teriflunomide
Primary endpoint
 Annualised relapse rate per year –30%
Secondary endpoints
 12-week confirmed disability accumulation –17%**
 Cumulative no. of combined unique active lesions –55%
 Change in FSIQ score –3.6 point (between-arm difference)
Exploratory endpoints
 24-week confirmed disability accumulation –16%**
 Cumulative no. of gadolinium-enhancing lesions –58%
 Change in whole brain volume 0.34% (between-arm difference)
 NEDA-3 +70%
 NEDA-4 +85%

Notes: *Unless indicated otherwise; **Not statistically significant.

Abbreviations: FSIQ, Fatigue Symptom and Impact Questionnaire; NEDA, no evidence of disease activity.